On June 8, 2023, Antisense Therapeutics announced that recruitment has commenced in the multicentre double-blind, placebo-controlled Phase IIb trial of ATL1102 in non-ambulant boys with Duchenne muscular dystrophy and the first participant has been randomized and dosed with ATL1102 or Placebo in Turkey.
To read their full press release, please click here.
To learn more about ATL1102, click here.
